OCS Stock Analysis: Buy, Sell, or Hold?
OCS - Oculis Holding AG Ordinary shares
$11.89
0.58 (5.13%)
▲
5d:
+7.89%
30d:
-15.79%
90d:
-56.73%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 20, 2026
16d
Get Alerted When OCS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OCS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: OCS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: OCS is currently trading at $11.89, which is considered slightly low relative to its 30-day fair value range of $11.38 to $13.49.
Technical Outlook: Technically, OCS is in a strong downtrend. The price is approaching resistance at $12.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $36.08 (+203.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OCS is in a strong downtrend. The price is approaching resistance at $12.15. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $36.08 (+203.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.38 -
$13.49
Company Quality Score
48/100
(HOLD)
Options IV Signal
67th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 67th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 203.5% below Wall St target ($36.08)
Trading Range Analysis
30-Day Trading Range
$11.38 -
$13.49
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$2.77
(23.3%)
Support & Resistance Levels
Support Level
$10.73
Resistance Level
$12.15
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.01
Wall Street Target
$36.08
(+203.5%)
Revenue Growth (YoY)
-26.7%
Share & Embed Analysis
Last updated: August 03, 2026 5:49 PM ET
Data refreshes hourly during market hours. Next update: 6:49 PM
Data refreshes hourly during market hours. Next update: 6:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
